Officials with the FDA have approved durvalumab (Imfinzi) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), in combination with standard-of-care (SoC) chemotherapies, in adult patients.
Overall cancer death rates declined by 29% over a 26-year time period, with the largest single-year drop on record reported from 2016 to 2017.
Investigational oral MET kinase inhibitor from Merck.
The FDA has recently approved new dosage form and two new indications for the drug.
Approved by the FDA in September, this new drug serves as a first-line therapy for patients with particular metastatic non-small lung cancer.